American Society of Hirudotherapy

Leech Thrombomodulin-binding factor

Modulates the thrombin-thrombomodulin axis — implications for protein C pathway.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Leech Thrombomodulin-binding factor11 kDa
Molecular weight (kilodaltons) of Leech Thrombomodulin-binding factor (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Mechanistic discussion
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

The reported thrombomodulin-binding activity is mechanistic only and does NOT establish clinical anticoagulant efficacy. No FDA-approved derivative exists; distinct from recombinant human thrombomodulin (ART-123/thrombomodulin alfa) developed by Asahi Kasei for DIC.

Molecular Profile

Category
Anticoagulant
Evidence tier
Preclinical
Molecular weight
11,000 Da
Source species
Hirudo medicinalis

Biological Targets

  • → thrombomodulin / thrombin / Protein C axis

External Resources

    Related Anticoagulant Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.